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Abstract   Effective verification and validation are central to medical device software de-
velopment and are essential for regulatory approval. Although guidance is available in mul-
tiple standards in the medical device software domain, it is difficult for the manufacturer to 
implement as there is no consolidated view of this information. Likewise, the standards and 
guidance documents do not consider process improvement initiatives. This paper assists in 
relation to both these aspects and introduces the development of processes for verification 
and validation in the medical device domain. 
Keywords: Medical device standards, Medical device software verification and 
validation, Medical device software process assessment and improvement 
1 Introduction 
Verification and Validation (V&V) activities are important activities in the soft-
ware development lifecycle and consume up to 50% of project development time 
[1], [2] and up to 50% of the total cost [3]. While both V&V play a key role in 
software development, there is a level of ambiguity in the use of these terms.  This 
is evident from the difference in definition of these terms in the literatures [4], [5] 
and [6].  
When developing safety-critical software it is imperative to have software de-
velopment practices which incorporate effective V&V activities.  In this context 
V&V are addressed by numerous standards for both generic and safety-critical 
software development which include specific medical device standards.  
The National Institute of Standards and Technology performed a study, indicat-
ing that software defects cost the U.S. economy in the region of $59.5 billion a 
year [7]. The study also indicates that better testing could detect and remove de-
fects early in the development process and reduce the cost by more than a third 
[7]. However, there are challenges in the implementation of V&V in the context of 
general software development and these challenges are even greater in safety-
critical domains. The requirements put forth by the regulatory bodies stress the 
need for supporting documentation and it can be challenging to satisfy these regu-
latory requirements and meet the pressures of the market at the same time.  
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2 V&V in Generic and Safety-Critical Software Development   
Two important reference models which are widely used in the context of software 
process improvement are the Capability Maturity Model® Integrated (CMMI
®
) 
[8] and ISO/IEC ISO/IEC 15504-5:2006  [9].  When considering software V&V it 
is of value to consider both. 
CMMI
®
 recommends a lifecycle approach for V&V activities. It defines verifi-
cation as ―Confirmation that work products properly reflect the requirements spec-
ified for them‖.  In other words, verification ensures that ―you built it right‖ and 
validation is ―Confirmation that the product, as provided (or as it will be provid-
ed), will fulfill its intended use‖. In this context, validation ensures that ‗you built 
the right thing‘. The V&V processes are part of the engineering processes catego-
ry and both are level 3 process areas in the staged model. The model also provides 
guidance in terms of examples of methods such as peer reviews; statement cover-
age testing and branch coverage testing that could be performed. The validation 
process area incrementally validates products against the customer‘s needs. Vali-
dation may be performed in the operational environment or simulated operational 
environment. Coordination with the customer in relation to validation require-
ments is an important element of this process area. The scope of the validation 
process area includes validation of products, product components, selected inter-
mediate work products, and processes. These validated elements may often require 
re-verification and re-validation. 
In ISO/IEC 15504-5:2006 V&V are two distinct processes and are part of the 
supporting lifecycle process group. Both of these processes are based on the re-
spective lifecycle processes in ISO/IEC 12207 AMD1 [10]. In ISO/IEC 15504-5, 
the purpose of the verification process is to confirm that each software work prod-
uct and/or service of a process or project properly reflects the specified require-
ments. The tasks pertaining to verification include: development of a verification 
strategy, development of criteria for verification, performing the activity of verifi-
cation, determination of actions based on verification results and making the re-
sults available to the stakeholders. 
CMMI
®
 and ISO/IEC15504-5 are not prescriptive when it comes to methods 
and tools to be used for V&V. Rather it is left to the discretion of the user to select 
and apply methods. Though CMMI
®
, considers validation and verification, it is 
still rather modest in its focus on these areas compared to other elements of the 
development processes [11]. Industry experiences indicate that V&V activities 
typically consume about 30-50% of development budgets [12].  
3 V&V for Safety-Critical Software Development   
Software can be a critical element of complex, potentially dangerous products 
such as weapons systems, aerospace systems and medical devices. These are criti-
cal because failure can result in loss of life, significant environmental damage, and 
major financial loss [13]. It has also been found that there is a relationship be-
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tween the increasing occurrence of system accidents and the increasing usage of 
software [15]. In these circumstances these products are required to meet a very 
high-level of reliability, security, and performance. Therefore, ensuring that such 
systems meet their predefined requirements and that they perform as expected is 
an essential and often challenging issue [14].   
Within the safety-critical software arena, different standards/certifications are 
available for different industries. These include the MIL-STD-498 [16] for mili-
tary applications, DO-178B [23] for Aerospace, and Automotive SPICE and ISO 
26262 [17] in the Automotive industry.  IEC 60880 [18] describes the European 
standards for the certification of nuclear power generating software.  IEC 61508 
[19] describes a general-purpose hierarchy of safety-critical development method-
ologies that has been applied to a variety of domains ranging from medical in-
strumentation to electronic switching of passenger railways. Though these stand-
ards address V&V in sufficient detail, their role is not to address process 
improvement. In addition, there are some [20] who consider that a CMMI
®
 V&V 
assessment inadequate when dealing with safety-critical software, and they pro-
pose a new framework for V&V assessment, focused on safety-criticality. This 
framework is defined through integrating safety standards with the V&V process 
areas of the CMMI
®
 and the ISO 9001 standard [21]. 
The following are some of the attributes of safety standards: (1) Product versus 
process (2) Safety management agents (3) Risk assessment (4) Integrity levels (5) 
Design safety and (6) Assurance techniques [22]. Based on these criteria, we de-
cided to use DO-178B and the Automotive SPICE as part of our research for de-
veloping V&V processes for the medical device software domain. Automotive 
SPICE has been derived from ISO/IEC 15504-5.  This was of particular relevance 
as it was developed for a safety-critical domain to facilitate process assessment 
and improvement.  
Therefore, existing software process reference models need to be adapted and 
extended to meet the specific requirements of medical device software develop-
ment which is safety-critical in nature.  
4 Research Approach and Outcomes 
The research involved a number of stages: 
1. The V&V processes were reviewed in detail and consideration was given 
to how they were addressed by generic software development standards 
and process improvement reference models, which included ISO/IEC 
12207, ISO/IEC 15504-5 and CMMI
®
.  
2.  A literature review of V&V was performed in terms of safety-critical 
software development. This included a review of the V&V processes ad-
dressed by safety-critical software development standards such as DO-
178B and Automotive SPICE [24]. 
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3.  A literature review and analysis was also performed in relation to medical 
device software V&V. This incorporated the Food and Drug Administra-
tion (FDA) guidelines for Software Validation (FDA GPSV) [25], the 
Medical Device Directive (MDD) 1993/42/EEC [26] and amendment 
2007/47/EC [27]  ,ISO/IEC 62304 [28],  ISO/IEC 13485 [29] and  
ISO/IEC 14971 [30].  
4.  Based on this analysis we defined a set of processes for V&V for medi-
cal device software development. The processes were assigned a Process 
ID, Process Name, Process Purpose, Process Outcomes and a set of Spe-
cific Practices.  Guidance in the implementation of these specific practic-
es is provided through a set of sub-practices and notes.  These processes 
were developed as part of the Medi SPICE [41].  
4.1 Regulatory Nature of the Medical Device Domain    
Studies in the medical device industry [31], [32], point to the fact that software is 
one of the most critical factors for cutting edge products and the role software 
plays is predicted to continue to increase [32]. It is also expected that, by 2015, the 
research and development investment in software in this area will increase from 
25% of the overall budget in 2002, to 33% [32]. 
However, as the role of software in the medical device domain increases, so do 
the number of failures which arise due to software defects. An analysis of medical 
device recalls by the FDA in 1996 [33] found that software was increasingly re-
sponsible for product recalls. This continues to be the case and in the period the 1
st
 
January 2010 to 1
st 
January 2011 the FDA recorded 80 medical device recalls and 
state software as the cause [46].  A German survey on medical device recalls indi-
cated that software was the top cause for risks related to construction and design 
defects of medical device products. This analysis, from June 2006, showed that 
21% of the medical device design failures were caused by software defects. This 
was an increasing trend, as the figures from November 2005 showed software was 
responsible for 17% of construction and design defects [34]. 
Due to the safety-critical nature of medical devices, medical device companies 
who wish to sell their products must comply with the regulatory requirements of 
the respective countries where they plan to market them. Medical devices can only 
be sold in the US if they comply with the FDA regulations [35], whereby a quality 
system needs to be in place that complies with the FDA Regulations 21 CFR Part 
820, Quality System Regulation (QSR) [36]. In order to sell devices the manufac-
turer not only has to prove safety and effectiveness, but also has to demonstrate 
that the design and development of the device including the software complies 
with the FDA regulations. The ―Guidance for the Content of Premarket Submis-
sions for Software Contained in Medical Devices‖ document [37] details these re-
quirements.  Though the regulatory bodies, such as the FDA provide guidance 
documents, they do not dictate that a particular method must be used [38]. The 
quality system process itself is designed by the medical device manufactures and 
the quality system process needs to ensure that the manufacturer is designing and 
5 
building a quality product. The difficult part is that the manufacturer has to pro-
vide evidence to the FDA inspectors that the correct processes have been followed 
[35].  
   In order to achieve standardization of expectations and for better guidance for 
implementation by manufacturers, the FDA Center for Devices and Radiological 
Health (CDRH) has published guidance documents which include risk-based ac-
tivities to be performed during software validation [25], pre-market submission 
[37] and when using off-the-shelf software in a medical device [39].  Although the 
CDRH guidance documents provide information on which software activities 
should be performed, they do not enforce any specific method for performing the-
se activities. The result is that the medical device manufacturers could fail to com-
ply with the expected requirements.  
Within the medical device industry a decision was initially made to recognize 
ISO/IEC 12207:1995 (a general software engineering lifecycle process standard) 
as being suitable for general medical device software development [10].  Howev-
er, upon careful examination of ISO/IEC 12207, the Association for the Ad-
vancement of Medical Instrumentation (AAMI) software committee decided it 
was necessary to create a new standard specifically for medical device software 
development. The AAMI used ISO/IEC 12207:1995 as the foundation for their 
new standard ―AAMI SW68, Medical device software – Software lifecycle pro-
cesses‖ [38]. In 2006, a new standard AAMI/IEC 62304 [28] was released that 
was based on the AAMI SW68 standard.  
In order to sell medical devices within the Europe Union (EU) the CE mark is 
required. To achieve the CE mark compliance is required with the Medical Device 
Directive (MDD) (1993/42/EEC) and amendment MDD (2007/47/EC), In-Vitro 
Diagnostic Directive (IVDD) [44] and the Active Implantable Medical Device Di-
rective (AIMDD) [45] depending on the type of medical device being submitted. 
As stated in the latest amendment to the MDD, Section 1 (g) of MDD 
(2007/47/EC) ―For devices which incorporate software or which are medical soft-
ware in themselves, the software must be validated according to the state of the art 
taking into account the principles of development lifecycle, risk management, val-
idation and verification‖. “State of the Art” is used here to mean what is generally 
accepted as good practice. Since this requirement was introduced, developers must 
now validate the software be it integrated or standalone, regardless of device class.  
IEC 62304 and its aligned standards are often seen as a good place to start when 
validating software.   Whilst these standards are generally accepted and are har-
monised under the MDD they do contain omissions which make them difficult to 
apply to standalone software as an active medical device.  As we had observed 
from our research this is exemplified by IEC 62304 where there is no provision 
within the standard to validate the system elements of standalone software. 
While there are numerous standards in the medical device domain they are ori-
ented towards achieving regulatory compliance.  As a result the focus of medical 
device software development is compliance rather than process improvement.   To 
address this Medi SPICE is being developed. The objective of Medi SPICE is to 
provide a process assessment and improvement model which is domain specific to 
medical device software development and incorporates regulatory compliance.  
The results of a Medi SPICE assessment may be used to indicate the state of a 
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medical device suppliers software practices in relation to the regulatory require-
ments of the industry, and identify areas for process improvement. The results of 
these assessments may also be used as a criterion for supplier selection. The au-
thors believe that, with the publication of the Medi SPICE more specific guidance 
will be available for the basis of process design and assessment in the medical de-
vice industry [41].  
4.2 V&V in Medi SPICE  
Based on our research which comprised of an extensive literature review and 
comparative analysis of standards in the medical device and other safety-critical 
domains, we arrived at the following findings, which were incorporated into the 
definition of the processes related to V&V in Medi SPICE: 
a. From the literature review and comparison across other standards and 
models, it became clear that the terms V&V are frequently used inter-
changeably. The FDA guidelines distinguish between verification and 
validation. Though the FDA is clear on the definition part, sections 4, 5 
and 6 of the FDA GPSV, which deals with operational activities, still use 
the term validation only and no reference is made to verification. Guid-
ance on differentiating between V&V activities with respect to the differ-
ent engineering activities/work products should be in place.  The amend-
ment 2007/47/EC to the MDD stresses the importance validation plays 
and the need for state of the art validation and verification  
b.  Verification is not addressed as a separate process in IEC 62304 and veri-
fication practices are integrated into other engineering processes. Valida-
tion is considered a systems level process and outside the scope of IEC 
62304 even when the system consists entirely of software.  
c. Automotive SPICE has V&V criteria and V&V records as outputs in its 
processes. The ISO/IEC 15504-5 does not go to this level of detail.  
d. The IEEE Standards for Software V&V state that classical Independent 
Verification & Validation (IV&V) is generally required for the develop-
ment of software systems deemed ―critical‖, i.e., those which can result 
in loss of life, mission or significant social or financial loss [42]. Inde-
pendence is an important factor addressed by DO-178B. The degree of 
independence is also addressed in ISO/IEC 15504-5 and Automotive 
SPICE. The FDA GPSV Sec 4.9 does address independence and leaves it 
to the discretion of device manufacturers as to how this is to be achieved. 
Independence is not addressed as part of IEC 62304 and it assumes that it 
is taken care of by/through ISO 13485. Therefore, in Medi SPICE we 
placed a particular focus on the clarity of independence in the verification 
and validation processes.   
e.  Software developed for medical devices concerns itself with obtaining 
regulatory approval as opposed to improving processes to achieve more 
efficient software development [40]. Models like CMMI
®
 and ISO/IEC 
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15504-5 have separate process areas for verification and validation. A 
separate process area for critical processes like V&V enable organiza-
tions to understand their strengths and weaknesses in a detailed manner 
and can provide help when embarking on process improvement initia-
tives.   
From our analysis of the relevant literature regarding V&V and through the 
comparative analysis of process improvement models and standards, our goal was 
to determine best practice in this area and to facilitate process improvement.  Our 
objective was also to satisfy the requirements of the relevant medical device 
standards which include the FDA GPSV, MDD, ISO/IEC 13485, IEC 62304, IEC 
TR 80002-1 [43] and ISO14971. Having established these elements, it was imper-
ative we incorporate them into Medi SPICE. To achieve this we developed the fol-
lowing Medi SPICE processes with a particular emphasis on verification and vali-
dation:  
1. Software Construction  
2. Software Integration 
3. Software Testing  
4. Verification  
5. Validation 
As discussed in Section 4, our objective was to incorporate the relevant stand-
ards and the most effective elements of process improvement models into a com-
mon framework specifically designed for the medical device software domain, 
Medi SPICE. 
Unlike ISO/IEC 15504-5, where there is no requirement for the classification of 
outcomes and processes based on safety, this was an important element which had 
to be included in Medi SPICE. We therefore utilized the classification schema 
provided by IEC 62304, which is used to associate the outcomes and specific prac-
tices with the safety level of the software for which the practices are applicable.  
While we based the practices on the ISO/IEC15504-5, our analysis of standards in 
similar safety-critical domains highlighted that it would be beneficial to use Au-
tomotive SPICE as our reference, as it is has been developed to meet the specific 
requirements of safety-critical software development. As a result of the findings 
from our research, we have included V&V as separate process areas in Medi 
SPICE. The validation process includes many of the recommendations that were 
produced as part of this research.  
Risk management is an integral part of medical device software development. 
In this context the relevant standards for medical device development are ISO 
14971 and IEC 62304. IEC/TR 80002-1 provides specific guidance as to how the-
se two standards can be combined to address risk with regard to medical device 
software development. The requirements of V&V as required by these standards 
have been addressed in the five processes listed above.  
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4.3 Summary of V&V related Processes in Medi SPICE  
For the purpose of this paper, we use the Software Testing (ENG.8) process in 
Medi SPICE as an example. This process relates to the IEC 62304 Software Sys-
tem Testing activity which has five tasks. As an outcome of our analysis, specific 
practices (1 to 10) were defined for the Software Testing Process. The practices 
and how they map to relevant medical device standards are illustrated in the Table 
1: 
Table 1: Mapping ISO/IEC 62304 Tasks to Medi SPICE practices   
IEC 62304 
Reference 
Sub Task / Clause Medi SPICE 
Reference 
Medi SPICE Reference 
5.7.1 Establish tests for 
software requirements 
ENG.8.SP1 Develop software test 
strategy 
    ENG.8.SP1.1 Establish a set of tests 
    ENG.8.SP2 Develop test specification 
for software test 
    ENG.8.SP4 Test the integrated software 
5.7.2 Use software problem 
resolution process 
ENG.8.SP5 Anomalies are recorded 
5.7.3 Retest after changes ENG.8.SP9 Develop regression test 
strategy and perform 
regression testing 
5.7.4 Verify software system 
testing 
ENG.8.SP3 Verify test specification for 
software test 
    ENG.8.SP7 Verify software testing 
5.7.5 Software system test 
record contents 
ENG.8.SP6 Record results of software 
test 
    ENG.8 SP8 Ensure consistency and 
bilateral traceability 
    ENG.8.SP10 Conduct risk management 
activities  
 
Against the five tasks that the IEC 62304 provides, the Medi SPICE Software 
Testing Process has nine specific practices and one sub practice. In line with the 
good practice of ensuring traceability at each engineering activity level as ob-
served in ISO/IEC 15504-5, Medi SPICE also focuses on using traceability in 
each engineering activity as it is very important from a verification perspective. In 
addition, to the specific practices a single sub-practice, additional implementation 
guidance is provided through 10 notes in the Software Testing Process.  It may be 
noted from Table 1 that a specific practice – Conduct risk control activities has 
been added as part of the model. We are thus providing guidance through Medi 
SPICE on risk management activities in line the ISO 14971, which requires verifi-
cation of the implementation of risk control, as well as verification of the reduc-
tion of risk through adopting risk control mechanisms.   
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Table 2, outlines how we have addressed some of the typical software testing 
tasks, with reference to the FDA GPSV guidance document. 
 
 
  
Table 2: Mapping FDA Typical tasks to Medi SPICE 
FDA Typical Tasks  Medi SPICE Reference 
Test Planning  Software Construction 
Functional test case identification Software Construction 
Traceability analysis Software Construction,  
Software Integration,  
Software Testing  
Unit (module) test execution Software Construction 
Integration test execution Software Integration 
Functional test execution Software Integration 
System test execution Software Testing 
Error evaluation/resolution Software Testing  
Final Test Report  Software Testing 
 
The requirements of FDA GPSV are directly addressed by Medi SPICE as can 
be observed from the mapping. Further, it needs to be noted that the task of Ac-
ceptance test execution is not addressed by Medi SPICE as part of software engi-
neering processes. This is in line with the Automotive SPICE as well as ISO/IEC 
15504-5, where acceptance testing is part of the acquisition group of processes. 
5 Conclusions and Future Work  
Further to the definition of a set of process areas and the associated practices relat-
ed to V&V, the processes should be piloted in organizations within the medical 
device software development industry. Based on the results observed, the process-
es should be evaluated and continuously improved based upon feedback from the 
medical device software development industry. 
Additionally, as V&V absorbs a significant amount of project time, further re-
search will be performed out on practices, which could bring in reduction in cycle 
time for V&V activities but without compromising quality and safety features of 
the products being developed.  
Globalization of software development has led to distributed teams working on 
the same product in different locations. Understanding the challenges in globally 
distributed V&V in the context of medical device software development and what 
additional practices could aid practitioners in such cases. These practices could 
then become notes or sub-practices in further versions of Medi SPICE.  
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As medical device manufacturers outsource their medical device software de-
velopment, it would be worthwhile to examine: (a) what could be drivers in out-
sourcing V&V activities to a third party. (b) if outsourcing of medical device 
software development is performed, will V&V still be done internally? (c) What   
risks should be considered and practices should be included in a reference model 
for medical device software development from a V&V perspective for 3rd party 
software (COTS) or where certain activities are outsourced? 
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